SurModics (SRDX) Reports Q3 EPS of $0.27, Revenues Beat; 'Raising Fiscal 2018 Revenue & EPS Guidance'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/7/2026

1. MRVL
2. ZS
3. PENG
4. STZ
5. SKYD
6. BBIO
7. RCKT
8. NVDA
9. CRBU
10. HALO

Go back to SurModics (SRDX) Reports Q3 EPS of $0.27, Revenues Beat; 'Raising Fiscal 2018 Revenue & EPS Guidance'

Surmodics Reports Third Quarter Fiscal 2018 Results

August 6, 2018 7:30 AM EDT

Raises Fiscal 2018 Revenue Guidance

EDEN PRAIRIE, Minn.--(BUSINESS WIRE)-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2018 third quarter ended June 30, 2018, and updated its financial outlook for fiscal 2018.

Summary of Third Quarter Fiscal 2018 and Recent Highlights

Revenue of $22.2 million, up 24.9% Raising revenue guidance range to $79.0 to $81.0 million GAAP EPS of ($0.20), Non-GAAP EPS of $0.27 Acquisition of thrombectomy... More